Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Australia wants to keep "rule of origin" in MRA (Mutual Recognition Agreement):

This article was originally published in Clinica

Executive Summary

A new hurdle has emerged in the Mutual Recognition Agreement between Australia and the EU. The Australian delegation wants to keep the so-called "rule of origin" in the MRA, meaning that the MRA could not be applied to manufacturers based outside Australia or Europe. Rules of origin are difficult to police and the EU has a tendency to drop them from such MRA agreements. The issue is currently being discussed within the European Commission's Directorate General Trade.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT055342

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel